Vaisman N, Zadik Z, Duchan R, Voet H, Lotan D, Drukker A
Department of Paediatrics B, Kaplan Hospital, Rehovot, Israel.
Pediatr Nephrol. 1994 Apr;8(2):201-4. doi: 10.1007/BF00865478.
Growth hormone (GH) has different known metabolic effects, among which are lipolysis and anabolic action. We have studied the changes in body composition of children with chronic renal failure (CRF) after 1 year of daily treatment with GH. Body fat percentage and fat body mass (FBM) were derived from four site skinfold measurements; lean body mass (LBM) from total body potassium (TBK) and mid-arm muscle circumference (MAMC); bone mineral density (BMD) was measured by dual photon absorptiometry. GH treatment had a positive effect on weight, height and MAMC, but no effect on LBM (as reflected by TBK), FBM and BMD. Z-scores were derived in order to compare subjects with a normal population. While no significant change in z-score was noticed for weight, height, MAMC, FBM and BMD, TBK decreased during treatment. We conclude that GH therapy does not ultimately increase LBM in CRF patients compared with other GH-treated groups.
生长激素（GH）具有多种已知的代谢作用，其中包括脂肪分解作用和合成代谢作用。我们研究了慢性肾功能衰竭（CRF）患儿每日接受GH治疗1年后身体成分的变化。体脂百分比和脂肪量（FBM）通过四处皮褶厚度测量得出；瘦体重（LBM）通过全身钾含量（TBK）和上臂中部肌肉周长（MAMC）得出；骨矿物质密度（BMD）通过双能光子吸收法测量。GH治疗对体重、身高和MAMC有积极影响，但对LBM（以TBK反映）、FBM和BMD没有影响。为了将受试者与正常人群进行比较，计算了Z分数。虽然体重、身高、MAMC、FBM和BMD的Z分数没有显著变化，但治疗期间TBK下降。我们得出结论，与其他接受GH治疗的组相比，GH治疗最终不会增加CRF患者的LBM。
